Stanford begins testing Pfizer COVID-19 vaccine on kids as young as 2

California
A vial of the Pfizer COVID-19 vaccine that contains roughly six doses is shown in an undated photo. (Al Seib/Los Angeles Times)

A vial of the Pfizer COVID-19 vaccine that contains roughly six doses is shown in an undated photo. (Al Seib/Los Angeles Times)

As statewide eligibility for the COVID-19 vaccine expands to residents 16 and older, researchers at Stanford Medicine have set their sights on an even younger group: children ages 2 to 5.

The medical school Wednesday began administering doses to children in the tender age group as part of a larger, three-phase trial of Pfizer-BioNech’s COVID-19 vaccine that will ultimately include children ages 6 months to 12 years.

“We want to protect children just as we want to protect adults from this disease,” said Dr. Yvonne Maldonado, the pediatric infectious diseases expert leading the trial at Stanford. “The goal is to have a pediatric vaccine available for all age groups from 6 months of age to adulthood.”

About 76 million Americans have been fully vaccinated against the novel coronavirus, according to the Centers for Disease Control and Prevention, but children remain unprotected even as they head back to school. Currently, the Pfizer vaccine is available to people age 16 and older, while the Moderna vaccine is available to people 18 and older.

Read the full story on LATimes.com.

Copyright 2021 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Most Popular

Latest News

More News